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ABSTRACT
Purpose: Automated bolus calculation may beneﬁt
patients with poorly controlled type 1 diabetes who
are relatively new to continuous subcutaneous insulin
infusion (CSII). This study investigated the effect of
automated bolus calculation on glucose variability,
glucose control, and diabetes-related quality of life in
patients with reasonably well-controlled type 1 diabetes,
accustomed to treatment with CSII for several years.
Methods: This open-label, single-center study in-
cluded 32 patients (mean age, 45.9 [15.1] years; 34%
male; disease duration, 27.3 [12.9] years; glycosylated
hemoglobin [HbA1c] level, 64.6 [12.5] mmol/mol
[8.1% (1.1%)]; CSII treatment, 9.0 [7.8] years) who
were randomly assigned to receive 4 months’ treat-
ment with a bolus calculator (n ¼ 14) or continuation
of standard care without a bolus calculator (n ¼ 18).
All participants received dietary counseling on carbo-
hydrate counting. Primary outcome was glucose var-
iability, as assessed by the SD of 7-point glucose
proﬁles. Secondary outcomes included HbA1c, rate
of (severe) hypoglycemia, and diabetes-related quality
of life.
Findings: After 4 months of follow-up, glucose
variability had improved in the bolus calculator group
compared with the control group (change, –0.8 [0.9]
vs 0.1 [0.9] mmol/L; P ¼ 0.030). Mean glucose levels
did not change in either group (0.4 [1.1] vs 0.3 [0.9]
mmol/L; P ¼ 0.95). There were also no differences in
change in hypoglycemia rate (–0.6 [1.6] vs –0.4 [1.6]
event per patient per week; P ¼ 0.67), HbA1c value
(–0.5 [6.6] vs –4.9 [10.6] mmol/mol; P ¼ 0.21), or
diabetes-related quality of life between the bolus
calculator group and the control group.
Implications: Use of a bolus calculator modestly
improved glucose variability in this relatively small
group of patients with longstanding type 1 diabetes on
CSII but did not affect other parameters of glycemic
control or diabetes-related quality of life. (Clin Ther.
2018;40:862–871) & 2018 The Authors. Published by
Elsevier HS Journals, Inc.
Key words: continuous subcutaneous insulin infu-
sion, bolus calculator, insulin therapy, glucose varia-
bility, type 1 diabetes.
INTRODUCTION
Various large-scale clinical trials have shown the
importance of near-normalization of glucose control
to reduce the risks of microvascular complications in
individuals with diabetes.1,2 Intensive insulin therapy
is paramount to achieving such good glycemic control
in patients with type 1 diabetes and in those with
prolonged type 2 diabetes approaching the insulin-
deﬁcient state.
Optimal insulin therapy requires patients to esti-
mate the amount of prandial insulin before each meal
according to several factors, including current glucose
level, anticipated carbohydrate intake, insulin-to-car-
bohydrate ratio (ICR), estimated insulin sensitivity,
target blood glucose level, and anticipated physical
activity.3 Adjustment of the insulin dose to carbo-
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hydrate intake has shown improvement in glycemic
control, treatment satisfaction, and patient’s well-
being.4,5 Previous studies, however, have shown that
more than one half of the patients estimate their
prandial insulin dose incorrectly,6,7 many because
they fear injecting too much insulin and causing
hypoglycemia.8 Patients with poor numeracy skills
have higher glycosylated hemoglobin (HbA1c) levels
compared with patients with good numeracy skills.9,10
Automatic bolus calculators have emerged to aid in
insulin bolus estimation, taking into account individu-
alized ICR and insulin sensitivity factor (ISF), as well as
the effect of previously administered insulin (ie, insulin
on board). In daily practice, however, such bolus
calculators are used by a minority of adult patients
receiving CSII. There is still uncertainty about the beneﬁt
of automated bolus calculation. Some studies have
shown improvements in glycemic control11 and quality
of life3,12 in poorly controlled patients treated with CSII
or multiple daily injections (MDIs),13–18 but others have
not.17,19 In most studies, however, extensive education
on carbohydrate counting accompanied the initiation of
the bolus calculator, which was not routinely provided
in the control situation. In addition, many participants in
studies involving CSII were new to this form of treat-
ment, and most studies excluded participants with
(relatively) good glucose control.12,16,20
The objective of the present study was to inves-
tigate whether a bolus calculator could still beneﬁt
patients with stable CSII treatment, for whom im-
provement of already moderate to good glycemic
control is not the primary aim of treatment. We
hypothesized that in such cases, the use of bolus
calculation would decrease glucose variability, reduce
the hypoglycemic burden, and, consequently, improve
diabetes-related quality of life without deteriorating
glucose control. To test this hypothesis, we conducted
a randomized controlled open-label trial in patients
with diabetes treated by CSII, in which both groups
received (repeated) dietary counseling at the start.
PATIENTS AND METHODS
Study Design
This 16-week, randomized controlled, single-cen-
ter, open-label study was performed at the Radboud
University Medical Center in Nijmegen, the Nether-
lands, between February 2014 and May 2016. The
study was approved by the local institutional review
board and performed according to the principles of
the Declaration of Helsinki. All participants provided
written informed consent.
Study Population
Patients with type 1 diabetes treated with CSII were
recruited from the outpatient clinic. People were eligible
for participation in the study when they met the following
criteria: treatment with CSII for at least 6 months, age
between 18 and 60 years, HbA1c value o86 mmol/mol
(10%), disease duration 42 years, and a total daily
insulin doseo1 U/kg. Key exclusion criteria were current
use of a bolus calculator, inability or unwillingness to
perform frequent blood glucose measurements, preg-
nancy or intention to become pregnant, prednisone
treatment, a recent cardiovascular event, or the presence
of severe microvascular complications. Although we
initially invited patients with long-duration type 2 dia-
betes to participate, only 2 patients were enrolled, both of
whom were randomized to the bolus calculation group.
Because of the low numbers and this imbalance, we
decided to exclude these patients from analysis.
Study Procedure
At the screening visit, participants completed var-
ious diabetes-related quality of life questionnaires
(Conﬁdence in Diabetes Self-Care scale, Hypoglyce-
mia Fear Survey, Problem Areas in Diabetes question-
naire), and HbA1c levels were measured. All
participants received dietary advice from a dietitian
concerning carbohydrate counting and insulin bolus
calculation; the knowledge thus acquired was tested
by examination. When participants failed this test,
they were scheduled for a second visit by a dietitian.
Subsequently, participants were randomized to either
the bolus calculator group or the control group. For
random allocation concealment, we used opaque,
sealed envelopes and blocks of 4 subjects.
The second visit occurred 2 weeks later. Partic-
ipants collected 7-point blood glucose proﬁles for 5
days before the visit and kept a diary about their
carbohydrate intake during these days. Participants
randomized to the bolus calculator group were con-
sulted by a diabetes educator to receive information
about use of the bolus calculator. ICR and ISF were
calculated based on the insulin total daily dose (TDD),
and ratios were programmed into the bolus calculator.
The ICR was calculated by using the 500 rule (ICR =
500 divided by TDD) and ISF by using the 100 rule
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(ISF = 100 divided by TDD).19,21,22 Target blood
glucose levels were determined individually, and
insulin on board time was set at 4 hours for each
participant. All participants were advised to maintain
their current lifestyle with respect to diet and physical
exercise during the study period. After 2 months,
participants again collected 7-point blood glucose
proﬁles for 5 days, and adjustments to pump settings
were performed if necessary.
Final assessment took place after 4 months at the
outpatient clinic. Participants again collected 7-point
blood glucose proﬁles for 5 days and completed a
diary about carbohydrate intake. Blood samples were
collected to determine HbA1c levels, and diabetes-
related quality of life was reassessed with the afore-
mentioned questionnaires.
Study Outcomes
The primary end point of this study was the change
in glucose variability, calculated from the 7-point
glucose proﬁles. Secondary end points were changes
in HbA1c, low blood glucose index (LBGI), high blood
glucose index (HBGI), the total amount of insulin
used, incidence of (severe) hypoglycemia, diabetes-
related quality of life, and presence of impaired
awareness of hypoglycemia.
Measurements
For blood glucose measurements, patients used
their own glucose meters. Patients continued using
their current insulin pump, and they started using the
bolus calculator that was provided by this pump.
Hypoglycemia was deﬁned as a self-measured glucose
level o3.0 mmol/L and severe hypoglycemia as those
events requiring assistance from another person for
recovery.23 HbA1c levels were measured by using the
Tosoh G8 HPLC-analyzer, distributed by Sysmex
Corporation (Kobe, Hyōgo Prefecture, Japan).
Diabetes-related quality of life was assessed by use
of questionnaires. The Hypoglycemia Fear Survey is
divided into 2 sub-questionnaires; fear that is man-
ifested in certain behavior (15 items) and in certain
worries (13 items). The behavior subscale is not
validated and was therefore not used. The worries
subscale has good reliability (Cronbach’s α ¼ 0.92). It
has a cutoff score of 20, with higher scores indicating
more fear of hypoglycemia.24,25 The Conﬁdence in
Diabetes Self-Care scale asks patients to indicate their
level of conﬁdence regarding daily activities related
to their diabetes (20 items). Scores range from 0 to
100, with higher scores reﬂecting more conﬁdence
in diabetes self-care. This test has a high internal
consistency in Dutch patients (Cronbach’s α = 0.86)
and high test–retest reliability (Spearman’s r = 0.85;
P o 0.0001).26 The Problem Areas in Diabetes
questionnaire consists of 20 items with possible
diabetes-related problems, for which patients need to
rate how much of a problem these items are at that
moment in their lives. Scores range from 0 to 100.
Higher scores indicate more diabetes-related distress,
and a score ≥40 is related to severe diabetes-related
distress. Internal consistency (Cronbach’s α ¼ 0.93–
0.95) and test–retest reliability (Pearson’s correlation
¼ 0.83) are high.27,28
We also assessed the status of awareness of hypo-
glycemia, using the Dutch-modiﬁed translation of the
Clarke questionnaire that was validated with hypo-
glycemic glucose clamps.29,30
Calculations and Statistical Analysis
Glucose variability was deﬁned by the SD of
7-point blood glucose proﬁles over 5 consecutive days.
The ICR, reﬂecting the amount of carbohydrates that
can be processed by 1 unit of insulin, was calculated
by dividing the amount of carbohydrates ingested by
the amount of insulin injected at that time. The ISF,
reﬂecting the blood glucose level response (in milli-
moles per liter) to 1 unit of insulin injected, was
calculated by dividing the fall in blood glucose level by
the amount of insulin used. The LBGI and HBGI were
calculated by using the EasyGV version 9.0.R2 (avail-
able free for noncommercial use at www.easygv.co.
uk) to assess the risks of hypoglycemia and hyper-
glycemia, respectively.31
We calculated that for the detection of a 20%
decrease in glucose variability at a 2-sided signiﬁcance
level of 0.05 with a power of 80%, the total number
of subjects needed would be 14 per group. To
account for dropouts, we thus aimed to enroll a total
of 30 subjects.
Data were analyzed by using IBM SPSS statistics
version 22 (IBM SPSS Statistics, IBM Corporation,
Armonk, New York). A total of 187 people were
screened for participation in this study, 48 of whom
were potentially eligible. Fourteen subjects were
excluded or withdrew consent before randomization.
Hence, the analysis included 32 participants: 14
randomized to the bolus calculator group and 18 to
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the control group. We performed an intention-to-treat
analysis on the remaining 32 patients. Missing data
were imputed by using inference methods. Student’s
independent 2-sample t tests were used to compare the
2 study groups and paired-samples t tests for the
calculation of within-groups changes over time. Two-
way ANOVA analyses were used to compare the
mean differences in blood glucose level and SDs
between the groups. Pearson’s χ2 analyses were used
for categorical variables. A P value o0.05 was
considered statistically signiﬁcant.
RESULTS
All patients randomized to treatment completed the
study (Figure 1). Baseline characteristics of the study
participants are presented in Table I. Groups were
comparable with regard to age, sex, disease duration,
HbA1c level, and history of microvascular complications.
Changes in Glycemic Parameters
The 7-point glucose proﬁles averaged over 5 days
are shown in Figure 2. There were no differences
between mean glucose levels at baseline and end of the
study for either the bolus calculator group (8.3 [1.2]
vs 8.7 [1.4] mmol/L; difference, 0.4 mmol/L [95% CI,
–0.4 to 1.1]; P ¼ 0.58) or the control group (8.2 [1.4]
vs 8.6 [1.5] mmol/L; difference, 0.3 mmol/L [95% CI,
–0.2 to 0.9]; P ¼ 0.07) at any time point or between
the groups (difference, 0.03 mmol/L [95% CI, –0.8 to
0.9]; P ¼ 0.95). Glucose variability, as assessed by the
SD of these proﬁles, declined signiﬁcantly in the bolus
calculator group over time but did not change in the
187 patients approached
139 patients not eligible because of:
48 patients eligible for
34 patients randomized
32 patients analyzed
Bolus calculator group, n = 14
Bolus calculator group, end of
Control group, n = 18
Control group, end of study,
n = 18study, n = 14
2 patients not analyzed because of:
Type 2 diabetes
participation
14 patients not randomized because of:
Lack of time/motivation
HbA1c value >10%
Unknown
Lack of time/motivation
Meeting exclusion criteria
Comorbidity: Asperger syndrome,
severe psoriasis
Participation in another study
-
-
-
-
-
-
-
-
Figure 1. Flow diagram showing patient selection. HbA1c ¼ glycosylated hemoglobin.
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control group (Figure 3). This change in glucose
variability in the bolus calculator group was
signiﬁcantly different from that in the control group
(–0.8 [0.9] vs 0.1 [0.9] mmol/L; difference, –0.9 mmol/L
[95% CI, –1.7 to –0.1]; P ¼ 0.030).
HbA1c fell slightly in both the bolus calculator
group and the control group, but neither effect nor the
difference between groups reached statistical signiﬁ-
cance (–0.5 [6.6] vs –4.9 [10.6] mmol/mol; difference,
4.3 mmol/mol [95% CI, –2.5 to 11.2]; P ¼ 0.21).
LBGI and HBGI also did not change (neither in the
bolus calculator group nor in the control group).
LBGI did not differ between groups (–1.3 [4.8] vs
0.3 [5.2]; difference, –1.6 [95% CI, –5.4 to 2.2] for
the bolus calculator group vs control group, respec-
tively; P ¼ 0.39). HBGI also did not differ between
groups (1.3 [5.3] vs 0.1 [3.7]; difference, 1.3 [95% CI,
–2.1 to 4.6] for the bolus calculator group vs the
control group; P ¼ 0.45) (Table II).
Hypoglycemia Rates
Frequency of biochemical hypoglycemia decreased
numerically in the bolus calculator group with 0.6
event per week (95% CI, –0.3 to 1.5; P ¼ 0.19) and
with 0.4 event per week in the control group (95% CI,
–0.5 to 1.2; P ¼ 0.39), but neither ﬁnding reached
statistical signiﬁcance. One patient in each group
experienced a severe hypoglycemic event. However,
the event in the bolus calculator group occurred
directly after randomization before the patient had
started to use the bolus calculator.
Diabetes-related Quality of Life
Neither fear of hypoglycemia nor diabetes-related
problems or conﬁdence in diabetes self-care changed
during follow-up in the bolus calculator group or in
the control group; there were no differences between
the groups (Table III). The average score on the
modiﬁed Clarke questionnaire changed with –0.2
(95% CI, –0.3 to 0.8; P ¼ 0.39) in the bolus
calculator group and with –0.1 (95% CI, –0.3 to
0.5; P ¼ 0.72) in the control group. None of the
patients in either group changed from normal
awareness to impaired awareness of hypoglycemia
or vice versa during the study period.
Subgroup Analysis
Subgroup analyses were performed for the primary
outcome based on age (≤50 vs 450 years), sex,
duration of CSII therapy (≤6 vs 46 years), and
Table I. Baseline characteristics. Unless otherwise indicated, data are mean (SD) or median (quartile 1,
quartile 3).
Characteristic Bolus Calculator (n ¼ 14) Control Group (n ¼ 18)
Male 6 (43%) 5 (28%)
Age, y 48 (15) 45 (15)
Weight, kg 81.7 (12.3) 76.6 (13.7)
Height, cm 172.4 (9.5) 173.1 (8.8)
Body mass index, kg/m2 27.6 (4.5) 25.6 (4.7)
Disease duration, y 28 (14) 27 (12)
Duration insulin pump therapy, y 7 (3, 13) 6 (2, 16)
Total insulin dose, IU 40 (13) 41 (23)
Basal/bolus insulin ratio 61/39 58/42
HbA1c, mmol/mol 65 (11) 64 (14)
HbA1c, % 8.1 (1.0) 8.0 (1.3)
History of microvascular complications 6 (43%) 6 (33%)
Retinopathy 4 (29%) 5 (28%)
Neuropathy 3 (21%) 3 (17%)
Nephropathy 2 (14%) 3 (17%)
History of peripheral vascular disease 1 (7%) 2 (11%)
History of cardiovascular events 0 0
Clinical Therapeutics
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HbA1c level (≤64 vs 464 mmol/mol). The decline in
glucose variability overall seemed to be mainly driven
by the subgroup of patients aged450 years, in whom
use of the bolus calculator reduced glucose variability
by 1.1 mmol/L (95% CI, –2.5 to 0.3) versus an
increase of 0.8 mmol/L (95% CI, –0.04 to 1.6) in
those randomized to the control group (difference,
–1.9 mmol/L [95% CI, –3.2 to –0.5]; P ¼ 0.019).
There was no change in glucose variability based on
differences in sex, duration of CSII therapy, or HbA1c
levels.
DISCUSSION
The main ﬁnding of the present study is that short-
term use of a bolus calculator in patients with type 1
diabetes on CSII for several years had a modest
beneﬁcial effect on glucose variability but did not
change overall glucose control, incidence of hypogly-
cemia, or diabetes-related quality of life. We also
found a negligible effect of the bolus calculator on
the prevalence of impaired awareness of hypoglycemia.
Our study is in agreement with several previous
studies showing no or minimal effects of the use of a
bolus calculator on glucose control. One study in
children and adolescents with type 1 diabetes on CSII
found a borderline decrease (P ¼ 0.056) in glucose
variability after 1 year of bolus calculator use but
observed no change in HbA1c levels.
19 Similarly,
Gross et al17 found no differences in average
deviation of postprandial glucose levels from target
in patients receiving CSII using a bolus calculator.
Another study also showed no improvement in
glucose control in patients treated with MDI and a
bolus calculator.12 We found no differences in
frequency of hypoglycemia after the start of using a
bolus calculator, again in line with results of other
studies.16,17,19
In contrast, other studies have reported an im-
provement in glucose control after use of a bolus
calculator in patients with CSII. Yamada et al16
showed a drop in HbA1c level in patients with type
1 diabetes who were started on a bolus calculator.
They included patients new to CSII therapy and use of
a bolus calculator. The differences in design may
partially explain the differences; although the study
by Yamada et al included new patients, our patients
were on CSII for almost 10 years. Garg et al18 found
improved glucose control in patients using insulin
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Figure 2. Mean blood glucose levels based on
7-point glucose profiles before the
study (open circles) and at the end
of study (closed circles), for the bolus
calculator group (top graph) and the
control group (bottom graph).
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guidance software (experimental group) because of
signiﬁcantly more glucose values within the target
range (3.89–8.33 mmol/L). However, patients in the
experimental group also performed a signiﬁcantly
higher number of self-monitoring of blood glucose
(SMBG) tests.
We found no improvement in diabetes-related qual-
ity of life after use of a bolus calculator, which is in
agreement with several other studies that examined
diabetes-related quality of life.11,20 The exception is 2
studies showing improvement in treatment satisfaction,
but not in other areas, among patients treated with
MDI.3,12 It is plausible that quality of life in our
participants was already at such a high level that
further improvement could not be achieved. Indeed,
baseline scores o25 for the Problem Areas in Diabetes
questionnaire in our participants reﬂect very little
diabetes-related distress. Alternatively, although many
patients report that the bolus calculator is easy to use
and preferred over self-calculations to determine insulin
doses,17 the associated need for self-measurement
and check for carbohydrate content may diminish
enthusiasm for the device.
In our study, subgroup analyses showed consistent
results in change in glucose variability. Further re-
search is needed to determine if elderly patients (aged
450 years) beneﬁt more from use of a bolus calcu-
lator compared with younger patients.
There are a number of potential explanations for
the limited beneﬁts of introducing automated bolus
calculation in our study. First, patients in our study
had a mean disease duration of 27 years, and they
were treated with CSII for almost 10 years on average.
Given this long duration, patients may already be
familiar with the principles of carbohydrate counting
and estimating required insulin doses. It is also
possible that they felt less comfortable with and were
therefore less likely to rely on advice from the bolus
Table II. Low blood glucose index (LBGI) and high blood glucose index (HBGI).
Variable Bolus Calculator Group Risk* Control Group Risk* P
LBGI
Baseline 7.3 (3.9) High 7.5 (5.0) High 0.88
End of study 6.0 (3.3) High 8.1 (5.5) High 0.21
HBGI
Baseline 10.2 (4.7) Moderate 9.6 (3.9) Low 0.68
End of study 11.5 (4.3) Moderate 10.7 (4.5) Moderate 0.61
*Risk of hypoglycemia/hyperglycemia; data are shown as mean (SD). Calculation of risk scores for LBGI: index ≤1.1 reﬂects a
minimal risk; index41.1 to ≤2.5 reﬂects a low risk; index42.5 to ≤5.0 reﬂects a moderate risk; and index45.0 reﬂects a
high risk of hypoglycemia. Calculation of risk scores for HBGI: index o5.0 reﬂects a minimal risk; index 45.0 to ≤2.5
reﬂects a low risk; index 42.5 to ≤5.0 reﬂects a moderate risk; and index 45.0 reﬂects a high risk of hyperglycemia.
Table III. Secondary outcome measurements:
quality of life. Values are given as
mean (SD).
Variable
Bolus
Calculator
Group
Control
Group P
CIDS
Baseline 86 (6) 87 (6) 0.72
End of study 85 (7) 87 (7) 0.34
PAID
Baseline 20 (20) 22 (15) 0.82
End of study 19 (17) 23 (17) 0.57
HFS
Baseline 16 (9) 14 (8) 0.72
End of study 15 (8) 16 (10) 0.81
CIDS ¼ Conﬁdence in Diabetes Self-Care scale (scores
range from 0–100, with higher scores reﬂecting more
conﬁdence); HFS ¼ Hypoglycemia Fear Survey (scores
range from 0–52, with higher scores reﬂecting more fear
of hypoglycemia); PAID ¼ Problem Areas in Diabetes
questionnaire (scores range from 0–100, with higher
scores reﬂecting more diabetes-related distress).
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calculator than on their own estimations. We did not
speciﬁcally select patients experiencing extreme glu-
cose excursions and excluded patients with very high
HbA1c levels but not those with optimal glycemic
control (HbA1c levels o53 mmol/mol [7%]). This
approach not only explained why patients in our
study were moderately controlled but also made it
harder to show added beneﬁt of an intervention aimed
at improving glycemic management. Therefore,
although not supported by our subgroup analysis,
we cannot exclude a potential beneﬁcial effect of
automated bolus calculation in patients with poor
glucose control or those recently starting insulin pump
therapy.
Our study has limitations. The study was random-
ized and controlled but not blinded. However, a
completely blinded trial would require a complicated
design that would in itself jeopardize generalization.
Although based on a power calculation, the number of
study subjects was relatively small and from 1 center
only, which limits generalizability. Glucose data were
collected from SMBG tests, which may provide less
information than continuous glucose monitoring
(CGM). However, current reimbursement restrictions
limit widespread implementation of CGM in clinical
practice, and thus most patients need to rely on
SMBG. The use of SMBG therefore better approaches
real-world practice in most patients compared with
CGM. Another limitation is the relative short duration
of the study. However, although the durability of the
effects of automated bolus calculation remains to be
determined, 4 months was sufﬁcient to detect differ-
ences in the primary outcome. In addition, most other
studies examining bolus calculators were of similarly
short duration.11,12,17 Strengths of this study are the
randomized controlled design and the homogeneity of
the study population. Furthermore, our control group
received equally intensive dietary education on carbo-
hydrate counting; thus, any differences between the
groups could be solely attributed to the bolus calcu-
lator per se.
CONCLUSIONS
Among patients with longstanding diabetes and mod-
erate glucose control on CSII, additional use of a
bolus calculator had limited beneﬁcial effects on
glucose variability but did not affect other glycemic
end points or diabetes-related quality of life. As such,
we believe that automated bolus calculation ﬁts in a
tailor-made personalized treatment strategy for indi-
viduals with sufﬁcient motivation for its use rather
than being implemented according to a one-size-ﬁts-all
approach.
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